Aratana Therapeutics Inc. (NASDAQ:PETX) has been given an average rating of “Buy” by the nine research firms that are presently covering the company. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $11.86.

PETX has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research report on Thursday, July 7th. Lake Street Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Aratana Therapeutics in a report on Sunday, July 17th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $11.00 target price on shares of Aratana Therapeutics in a report on Wednesday, August 10th. Barclays PLC dropped their target price on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th.

In other Aratana Therapeutics news, insider Julia A. Stephanus sold 30,000 shares of the stock in a transaction dated Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total transaction of $187,500.00. Following the completion of the transaction, the insider now owns 127,503 shares of the company’s stock, valued at approximately $796,893.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $9.25, for a total transaction of $462,500.00. Following the transaction, the insider now directly owns 642,793 shares of the company’s stock, valued at approximately $5,945,835.25. The disclosure for this sale can be found here. Company insiders own 6.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Advisors LLC increased its position in Aratana Therapeutics by 3.6% in the second quarter. BlackRock Advisors LLC now owns 15,915 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 547 shares during the period. American International Group Inc. increased its position in Aratana Therapeutics by 10.6% in the second quarter. American International Group Inc. now owns 19,201 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 1,841 shares during the period. Metropolitan Life Insurance Co. NY bought a new position in Aratana Therapeutics during the second quarter valued at approximately $162,000. Parametric Portfolio Associates LLC increased its position in Aratana Therapeutics by 16.6% in the second quarter. Parametric Portfolio Associates LLC now owns 27,958 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 3,989 shares during the period. Finally, Trexquant Investment LP bought a new position in Aratana Therapeutics during the second quarter valued at approximately $188,000. 85.56% of the stock is owned by institutional investors and hedge funds.

Aratana Therapeutics (NASDAQ:PETX) opened at 9.13 on Monday. The stock’s market cap is $323.34 million. Aratana Therapeutics has a 12-month low of $2.56 and a 12-month high of $17.63. The stock has a 50 day moving average price of $9.05 and a 200 day moving average price of $6.93.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.37. Aratana Therapeutics had a negative net margin of 166.67% and a negative return on equity of 17.53%. The firm earned $38.05 million during the quarter, compared to the consensus estimate of $15.14 million. During the same quarter in the previous year, the firm posted ($0.23) EPS. On average, analysts forecast that Aratana Therapeutics will post ($0.77) earnings per share for the current fiscal year.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

5 Day Chart for NASDAQ:PETX

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.